STLN Starling Oncology, Inc.
Services-Offices & Clinics of Doctors of Medicine · Nasdaq · SEC CIK 1799191 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY21.7%
TTM net income YoY5.6%
TTM EPS YoY16.9%
Revenue 3-yr CAGR25.5%
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-8.9%
Net margin-14.4%
FCF margin-6.0%
EBITDA margin-7.4%
Returns
ROE-4,132.2%
ROA-38.7%
ROIC (approx.)-67.7%
Asset turnover2.69x
Leverage & solvency
Liabilities / assets107.5%
Debt / equity—
Current ratio1.68x
Interest coverage-3.90x
Cash quality & payout
Operating cash flow / net income0.36x
Accruals ratio-24.8%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $169.77M | $161.28M | $147.44M | $141.96M | $136.56M | $119.80M | $104.41M | $100.27M |
| SG&A expense | $32.13M | $29.94M | $28.21M | $28.04M | $25.25M | $26.91M | $25.38M | $24.86M |
| Operating income | -$2.98M | -$4.62M | -$6.51M | -$6.91M | -$8.05M | -$11.21M | -$9.91M | -$11.93M |
| Interest expense | $1.81M | $1.86M | $1.93M | $1.92M | $1.92M | $1.87M | $5.57M | $1.17M |
| Pretax income | -$15.75M | -$9.79M | -$2.49M | -$7.51M | -$16.50M | -$17.14M | -$19.59M | -$13.18M |
| Income tax | $0 | $0 | $0 | $0 | $0 | -$131,000 | $0 | $0 |
| Net income | -$15.75M | -$9.79M | -$2.49M | -$7.51M | -$16.50M | -$17.01M | -$19.59M | -$13.18M |
| EBITDA | -$1.46M | -$2.78M | -$4.90M | -$5.28M | -$6.33M | -$9.41M | -$8.13M | -$10.22M |
| EPS (basic) | -0.13 | -0.08 | -0.02 | — | -0.14 | -0.15 | -0.21 | — |
| EPS (diluted) | -0.13 | -0.08 | -0.02 | — | -0.14 | -0.15 | -0.21 | — |
| Weighted avg. shares (diluted) | 104.73M | 103.03M | 101.80M | — | 97.47M | 93.20M | 77.10M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $36.90M | $41.09M | $30.28M | $33.56M | $27.66M | $30.29M | $39.74M | $49.67M |
| Short-term investments | — | — | — | — | — | — | — | $0 |
| Receivables | $60.68M | $66.35M | $58.13M | $59.00M | $59.64M | $55.66M | $49.32M | $48.34M |
| Inventory | $36.63M | $20.01M | $24.29M | $16.88M | $18.88M | $15.79M | $12.31M | $10.04M |
| Current assets | $137.69M | $128.99M | $116.86M | $112.75M | $110.09M | $104.79M | $106.82M | $112.42M |
| PP&E, net | $10.59M | $10.58M | $10.70M | $10.68M | $10.71M | $10.85M | $11.12M | $11.89M |
| Goodwill | $7.23M | $7.23M | $7.23M | $7.23M | $7.23M | $7.23M | $7.23M | $7.23M |
| Intangibles | $8.87M | $9.59M | $10.30M | $11.02M | $11.73M | $12.45M | $14.04M | $14.81M |
| Total assets | $187.77M | $178.23M | $168.23M | $164.66M | $163.62M | $159.80M | $164.00M | $172.72M |
| Current liabilities | $123.70M | $94.94M | $79.35M | $70.96M | $65.58M | $64.78M | $59.54M | $52.22M |
| Long-term debt | $72.52M | $79.87M | $78.61M | $77.40M | $76.19M | $75.02M | $73.89M | $93.13M |
| Total debt | $72.52M | $79.87M | $78.61M | $77.40M | $76.19M | $75.02M | $73.89M | $93.13M |
| Total liabilities | $225.13M | $203.15M | $184.51M | $180.38M | $175.89M | $168.78M | $158.93M | $169.13M |
| Shareholders' equity | -$37.35M | -$24.91M | -$16.29M | -$15.72M | -$12.27M | -$8.98M | $5.07M | $3.59M |
| Net debt | $35.62M | $38.77M | $48.33M | $43.84M | $48.54M | $44.73M | $34.16M | $43.46M |
| Shares outstanding | 101.99M | 100.47M | 99.97M | 98.86M | 97.57M | 93.28M | 88.93M | 75.74M |
| Cash flow statement | ||||||||
| Operating cash flow | $10.14M | $11.94M | -$2.21M | $3.23M | -$12.63M | -$10.20M | -$4.99M | $4.00M |
| Capital expenditure | $1.26M | $908,000 | $1.04M | $1.06M | $604,000 | $1.21M | $328,000 | $1.75M |
| Free cash flow | $8.88M | $11.03M | -$3.26M | $2.17M | -$13.23M | -$11.41M | -$5.32M | $2.25M |
| Investing cash flow | -$1.26M | -$908,000 | -$1.04M | -$1.06M | -$604,000 | -$1.21M | -$202,000 | -$1.75M |
| Financing cash flow | -$13.08M | -$218,000 | -$28,000 | $3.73M | $10.60M | $1.96M | -$4.74M | -$164,000 |
| Depreciation & amortization | $1.52M | $1.84M | $1.62M | $1.63M | $1.72M | $1.80M | $1.78M | $1.71M |
| Stock-based compensation | $1.35M | $1.07M | $1.69M | $1.32M | $1.02M | $752,000 | $1.46M | $1.29M |
| Share buybacks | — | — | — | — | — | — | — | $0 |
Free plan shows the latest 8 periods; Pro shows all 27 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.